Hormonal
Sleep disruption leads to metabolic dysregulation (decreased insulin sensitivity, altered leptin/ghrelin) increasing the risk of obesity, metabolic syndrome, and type 2 diabetes.
Poor sleep disrupts the hormones that control hunger (ghrelin increases, leptin decreases) and reduces your body's ability to use insulin. This makes you more likely to gain weight and develop type 2 diabetes, even if your diet and exercise habits haven't changed. Fixing sleep continuity is a key metabolic intervention.
Suppression of SWS was associated with decreased insulin sensitivity... Other metabolic changes include decreased leptin and increased ghrelin that may contribute to increased appetite... Long-term consequences of sleep disruption in otherwise healthy individuals include... weight-related issues, metabolic syndrome, type 2 diabetes mellitus...
Why this rating
Supported by experimental studies on insulin sensitivity and large longitudinal studies/meta-analyses showing increased relative risk for T2DM.
Source
Short- and long-term health consequences of sleep disruption
Goran Medić et al. · Nature and Science of Sleep · 2017
DOI 10.2147/nss.s134864
More from this paper
- Sleep disruption (fragmentation/continuity loss) causes increased sympathetic nervous system activity and HPA axis activation, leading to short-term stress responsivity and long-term cardiovascular disease risk.Good
- Sleep disruption is associated with an increased risk of certain cancers (colorectal, breast, prostate) and all-cause mortality, particularly in men.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →